Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 9:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Coronary Graft Patency Clear all
Recruiting Not applicable Interventional

XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

NCT06895070
View directory record Official record
Conditions
Heart Transplant, Heart Failure, Transplant; Failure, Heart
Interventions
Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)
Device
Lead sponsor
XVIVO Perfusion
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 17, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

NCT02013037
View directory record Official record
Conditions
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy, Heart Graft Dysfunction
Interventions
Eculizumab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 17, 2026, 9:36 PM EDT
No Longer Available No phase listed Expanded access

Aprotinin US Special Access Protocol

NCT00611845
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Aprotinin (Trasylol, BAYA0128)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Decatur, Alabama • Glendale, California • Pismo Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2014 · Synced Sep 17, 2026, 9:36 PM EDT
Terminated Not applicable Interventional

Acupuncture and Post-Surgical Wound Healing

NCT00260494
View directory record Official record
Conditions
Postoperative Complications, Surgical Wound Infection, Surgical Wound Dehiscence
Interventions
acupuncture, sham acupuncture
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Sep 17, 2026, 9:36 PM EDT
Completed Phase 4 Interventional Results available

Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

NCT00369382
View directory record Official record
Conditions
Graft Rejection, Kidney Failure
Interventions
cyclosporine or tacrolimus, sirolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
8
States / cities
Tampa, Florida • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Sep 17, 2026, 9:36 PM EDT
Not listed Phase 1 Interventional

A Study of Anginera In Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

NCT00364390
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Anginera, a human tissue replacement therapy
Drug
Lead sponsor
Theregen, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
New Haven, Connecticut • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2009 · Synced Sep 17, 2026, 9:36 PM EDT
Recruiting Not applicable Interventional

The Relationship Between Blood Flow Readings During Surgery and How Well the Graft Stays Open and How Patients Recover Afterward in Coronary Artery Bypass Graft Surgery

NCT07485738
View directory record Official record
Conditions
CABG Graft Integrity, CABG, Blood Flow, Transit-time Flow Measurement, Heart Disease
Interventions
Transit-Time Flow Measurement (TTFM)
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 17, 2026, 9:36 PM EDT
Completed Phase 4 Interventional Results available

Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

NCT02053909
View directory record Official record
Conditions
Saphenous Vein Graft Disease
Interventions
Aspirin, Ticagrelor
Drug
Lead sponsor
Boca Raton Regional Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Sep 17, 2026, 9:36 PM EDT
Completed Phase 4 Interventional

Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery

NCT03900026
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Atherosclerosis, Vein Occlusion
Interventions
Evolocumab, Placebo
Drug · Other
Lead sponsor
Unity Health Toronto
Other
Eligibility
18 Years and older
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
San Francisco, California • Jacksonville, Florida • Portland, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 17, 2026, 9:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical and Hospital Stay Effects of Reiki and Manual Therapy After Open Heart Surgery

NCT05853250
View directory record Official record
Conditions
Coronary Artery Diseases, Valvular Heart Diseases
Interventions
Reiki/manual therapy
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 17, 2026, 9:36 PM EDT
Terminated Phase 4 Interventional Results available

Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion

NCT01246011
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Presence of Heparin/Platelet Factor 4 Antibody
Interventions
Argatroban and warfarin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 17, 2026, 9:36 PM EDT
Not listed Phase 3 Interventional

Cardiac CAtheterization for Bypass Graft Patency Rate Optimization: the CABG-PRO Randomized-controlled Pilot Study

NCT01063491
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery
Interventions
bypass graft angiography
Procedure
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 17, 2026, 9:36 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Multicenter Clinical Study On the High Vacuum Body Cavity Drainage System Following Open Heart Surgery

NCT00581399
View directory record Official record
Conditions
Coronary Artery Disease, Heart Valve Disease
Interventions
NO-NUMO™ High Vacuum Body Cavity Drainage System, PVC Chest Tube
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2011 · Synced Sep 17, 2026, 9:36 PM EDT
Completed Phase 4 Interventional Results available

Multicenter Infection Surveillance Study Following Open Heart Surgery

NCT00673712
View directory record Official record
Conditions
Surgery, Pneumonia, Surgical Site Infection
Interventions
Continuous Sternal Block, Opioid based analgesia
Device · Drug
Lead sponsor
Halyard Health
Industry
Eligibility
18 Years and older
Enrollment
647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Birmingham, Alabama • Newark, Delaware • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 17, 2026, 9:36 PM EDT
Completed No phase listed Observational

Study to Improve Long Term Vein Graft Patency After Coronary Bypass Surgery by Using a Novel Endoscopic Harvesting Technique

NCT01540422
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Dallas, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 17, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

NCT00300274
View directory record Official record
Conditions
Graft Rejection
Interventions
everolimus, mycophenolate mofetil, cyclosporine, corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Sep 17, 2026, 9:36 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery

NCT07646210
View directory record Official record
Conditions
Advanced Heart Failure, Ischemic Heart Failure
Interventions
HiCM-188 Cells
Drug
Lead sponsor
HELP Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 17, 2026, 9:36 PM EDT
Completed Not applicable Interventional

VEST Venous Graft External Support Pivotal Study

NCT03209609
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
VEST, Coronary artery bypass vein grafts
Device · Procedure
Lead sponsor
Vascular Graft Solutions Ltd.
Industry
Eligibility
21 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
14
States / cities
Los Angeles, California • Fort Wayne, Indiana • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 17, 2026, 9:36 PM EDT
Completed Not applicable Interventional

SMART Trial Longitudinal Follow-Up:Off-Pump Versus On-Pump Coronary Artery Bypass Surgery

NCT00209053
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary Artery Bypass
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 15, 2013 · Synced Sep 17, 2026, 9:36 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Aspirin and Plavix Following Coronary Artery Bypass Grafting

NCT01158703
View directory record Official record
Conditions
Coronary Graft Patency
Interventions
clopidogrel, sugar pill, Aspirin
Drug
Lead sponsor
Ahmad Slim
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Sep 17, 2026, 9:36 PM EDT
Terminated Phase 3 Interventional

CIS001 Extension Study of Cyclosporine Inhalation Solution

NCT00938236
View directory record Official record
Conditions
Lung Transplant
Interventions
Cyclosporine Inhalation Solution (CIS)
Drug
Lead sponsor
APT Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2012 · Synced Sep 17, 2026, 9:36 PM EDT
Completed Phase 3 Interventional

Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy

NCT00097968
View directory record Official record
Conditions
Graft Rejection
Interventions
everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
6
States / cities
Los Angeles, California • Minneapolis, Minnesota • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2010 · Synced Sep 17, 2026, 9:36 PM EDT
Terminated Phase 1 Interventional

Stem Cell Injection to Treat Heart Damage During Open Heart Surgery

NCT01557543
View directory record Official record
Conditions
Heart Disease, Ischemic Heart Disease, Coronary Artery Disease, Coronary Artery Disease (CAD)
Interventions
Cell Therapy
Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 17, 2026, 9:36 PM EDT
Active, not recruiting Not applicable Interventional

XVIVO Heart Perfusion System (XHPS) With Supplemented XVIVO Heart Solution (SXHS)

NCT05881278
View directory record Official record
Conditions
Heart Failure, Transplant; Failure, Heart
Interventions
Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
Device
Lead sponsor
XVIVO Perfusion
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 17, 2026, 9:36 PM EDT